Rethinking Clinical Trials

FEBRUARY 28, 2024

There are 5 guiding principles for defining quality that should inform DCTs: Have we enrolled the right participants according to the protocol with adequate consent? Did participants receive the assigned treatment and did they stay on the treatment? What we often do not think about is verifying the identity of the participant.

Clinical Trials 143

Clinical Trials Clinical Trials Trials Clinical Research 143

Rethinking Clinical Trials

DECEMBER 20, 2023

First, increasing diversity among trial participants must be a top priority in order to address health disparities and allow for optimal diagnosis and management of CVD in all. Increasing diversity in trial leadership is one of the most important strategies to increase diversity among RCT participants.

Clinical Trials 173

Clinical Trials Clinical Trials Trials Cardiology 173

Rethinking Clinical Trials

JANUARY 19, 2023

But this might obscure heterogeneity within groups, intersecting sources of vulnerability, and other vulnerable participants, such as people with dementia. One definition of vulnerability is “an identifiably increased likelihood of incurring additional or greater wrongs,” as a result of research participation. it can be a barrier.

Trials 130

Trials Clinical Trials Clinical Trials Research 130

Rethinking Clinical Trials

JULY 19, 2023

in which participants had type 2 diabetes mellitus and ASCVD. The intervention included assessment of local practices and barriers, development of strategies to overcome those barriers, and audit and feedback of quality metrics, with the goal of improving the way clinics approach treatment of these diseases. Granger, MD; Neha J.

Trials 130

Trials Cardiology Medicine Nurses 130

Rethinking Clinical Trials

AUGUST 23, 2022

There is a national priority to increase diversity in clinical trials, from regulatory, funding agencies, industry, and others, so that the participant population reflects the U.S. population at large, which is steadily becoming more diverse. It was held virtually on April 28-29, 2021. Learn more. pctGR, @Collaboratory1.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Medicine 130

Rethinking Clinical Trials

OCTOBER 2, 2023

There are more than 50 organizations with participating in PROTEUS, including clinicians and patient advocates, research and methods organizations, clinical trials groups, funding and government agencies, and universities and health systems. The Advisory Group identified 47 different potential solutions to address the top barriers.

Clinical Trials 154

Clinical Trials Clinical Trials Research Trials 154

Rethinking Clinical Trials

DECEMBER 6, 2022

Medication adherence can be a barrier to effectiveness. There was 1:1 randomization of participants to either the mHealth intervention or usual care. Can you talk about the compensation of participants? – Was it easier or harder than expected to recruit participants? Discussion Themes. One pays more than another.

Trials 130

Trials Clinical Trials Clinical Trials Compliance 130